Last10K.com

Mymd Pharmaceuticals, Inc. (MYMD) SEC Filing 10-K Annual Report for the fiscal year ending Friday, December 31, 2021

Mymd Pharmaceuticals, Inc.

CIK: 1321834 Ticker: MYMD
Cover - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Mar. 31, 2022
Jun. 30, 2021
Cover [Abstract]    
Document Type10-K   
Amendment Flagfalse   
Document Annual Reporttrue   
Document Transition Reportfalse   
Document Period End DateDec. 31, 2021   
Document Fiscal Period FocusFY   
Document Fiscal Year Focus2021   
Current Fiscal Year End Date--12-31   
Entity File Number001-36268   
Entity Registrant NameMyMDPharmaceuticals, Inc.   
Entity Central Index Key0001321834   
Entity Tax Identification Number22-2983783   
Entity Incorporation, State or Country CodeNJ   
Entity Address, Address Line One855 N. Wolfe Street   
Entity Address, Address Line TwoSuite 601   
Entity Address, City or TownBaltimore   
Entity Address, State or ProvinceMD   
Entity Address, Postal Zip Code21205   
City Area Code856   
Local Phone Number848-8698   
Title of 12(b) SecurityShares of common stock, no par value   
Trading SymbolMYMD   
Security Exchange NameNASDAQ   
Entity Well-known Seasoned IssuerNo   
Entity Voluntary FilersNo   
Entity Current Reporting StatusYes   
Entity Interactive Data CurrentYes   
Entity Filer CategoryNon-accelerated Filer   
Entity Small Businesstrue   
Entity Emerging Growth Companyfalse   
Entity Shell Companyfalse   
Entity Public Float   $ 21,254,305
Entity Common Stock, Shares Outstanding  38,058,245 
Documents Incorporated by ReferenceNone.   
ICFR Auditor Attestation Flagfalse   
Auditor Firm ID536677  
Auditor NameMorison Cogen LLPCHERRY BEKAERT LLP  
Auditor LocationBlueBell, PennsylvaniaTampa,Florida  

View differences made from one year to another to evaluate Mymd Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Mymd Pharmaceuticals, Inc..

Continue

Assess how Mymd Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Mymd Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Financial
M & A
Legal
Other
Filter Subcategory:
All
Shares
Expense
Debt
Other
Inside Mymd Pharmaceuticals, Inc.'s 10-K Annual Report:

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Cover
Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets (Parenthetical)
Condensed Consolidated Statements Of Comprehensive Loss
Consolidated Statement Of Changes In Stockholders' Equity/(Deficit)
Consolidated Statement Of Changes In Stockholders' Equity/(Deficit) (Parenthetical)
Consolidated Statements Of Cash Flows
Commitments And Contingencies
Commitments And Contingencies (Details Narrative)
Employee Benefit Plan
Employee Benefit Plan (Details Narrative)
Equity
Equity (Details Narrative)
Equity (Tables)
Income Taxes
Income Taxes (Details Narrative)
Income Taxes (Tables)
Notes Payable
Notes Payable (Details Narrative)
Organization And Description Of Business
Organization And Description Of Business (Details Narrative)
Patent Assignment And Royalty Agreement
Paycheck Protection Program Loan
Paycheck Protection Program Loan (Details Narrative)
Recent Developments, Liquidity And Management???S Plans
Recent Developments, Liquidity And Management???S Plans (Details Narrative)
Recent Developments, Liquidity And Management???S Plans (Tables)
Related Parties
Related Parties (Details Narrative)
Schedule Of Anti-Dilutive Securities Excluded From Computation Of Earnings Per Share (Details)
Schedule Of Condensed Consolidated Balance Sheet Information Related To Operating Lease (Details)
Schedule Of Deferred Tax Assets And Related Valuation Allowances (Details)
Schedule Of Estimated Useful Lives Of Property Plant And Equipment (Details)
Schedule Of Income Tax (Benefit)/ Provision (Details)
Schedule Of Lease Cost (Details)
Schedule Of Marketable Securities (Details)
Schedule Of Net Assets Acquired To Be Allocated To Goodwill (Details)
Schedule Of Operating Lease Minimum Lease Payments (Details)
Schedule Of Other Information Related To Leases (Details)
Schedule Of Reconciliation Of Income Taxes Using Statutory U.S. Income Tax Rate And Benefit From Income Taxes (Details)
Schedule Of Trade And Other Payables (Details)
Significant Accounting Policies
Significant Accounting Policies (Details Narrative)
Significant Accounting Policies (Policies)
Significant Accounting Policies (Tables)
Stock - Based Compensation
Stock - Based Compensation (Details Narrative)
Stock - Based Compensation (Tables)
Summary Of Milestone Events Payment (Details)
Summary Of Milestone Events Payment (Details) (Parenthetical)
Summary Of Restricted Stock Units Activity (Details)
Summary Of Stock Options Activity (Details)
Summary Of Warrant Activity (Details)
Trade And Other Payables
Trade And Other Payables (Tables)
Ticker: MYMD
CIK: 1321834
Form Type: 10-K Annual Report
Accession Number: 0001493152-22-008546
Submitted to the SEC: Thu Mar 31 2022 5:12:33 PM EST
Accepted by the SEC: Thu Mar 31 2022
Period: Friday, December 31, 2021
Industry: In Vitro And In Vivo Diagnostic Substances

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/mymd/0001493152-22-008546.htm